Adaptive Biotechnologies Corp. (ADPT)
26.89
-2.95
(-9.89%)
USD |
NASDAQ |
Oct 06, 16:00
26.96
+0.07
(+0.26%)
After-Hours: 20:00
Adaptive Biotechnologies Cash from Operations (Quarterly) : -6.40M for June 30, 2026
Cash from Operations (Quarterly) Chart
Historical Cash from Operations (Quarterly) Data
| Date | Value |
|---|---|
| June 30, 2026 | -6.40M |
| March 31, 2026 | -9.537M |
| December 31, 2025 | 2.055M |
| September 30, 2025 | -7.127M |
| June 30, 2025 | -12.43M |
| March 31, 2025 | -28.48M |
| December 31, 2024 | -12.49M |
| September 30, 2024 | -27.06M |
| June 30, 2024 | -17.30M |
| March 31, 2024 | -38.35M |
| December 31, 2023 | -26.93M |
| September 30, 2023 | -46.68M |
| June 30, 2023 | -23.56M |
| March 31, 2023 | -59.15M |
| December 31, 2022 | -30.02M |
| September 30, 2022 | -42.41M |
| June 30, 2022 | -47.06M |
| Date | Value |
|---|---|
| March 31, 2022 | -64.45M |
| December 31, 2021 | -53.83M |
| September 30, 2021 | -43.44M |
| June 30, 2021 | -37.21M |
| March 31, 2021 | -58.24M |
| December 31, 2020 | -39.84M |
| September 30, 2020 | -47.16M |
| June 30, 2020 | -31.08M |
| March 31, 2020 | -31.61M |
| December 31, 2019 | -26.79M |
| September 30, 2019 | -30.14M |
| June 30, 2019 | -15.97M |
| March 31, 2019 | 278.30M |
| December 31, 2018 | |
| September 30, 2018 | |
| June 30, 2018 | -9.066M |
| March 31, 2018 | -6.097M |
Cash From Operations Definition
Represents the net cash flow from the company's business operations.
Cash from Operations (Quarterly) Range, Past 5 Years
--
Minimum
--
Maximum
--
Average
--
Median
Cash from Operations (Quarterly) Benchmarks
| Personalis, Inc. | -25.77M |
| 10X Genomics, Inc. | 16.97M |
| Alamar Biosciences, Inc. (California) | -11.32M |
| Champions Oncology, Inc. | -0.492M |
| Medpace Holdings, Inc. | 162.01M |
Cash from Operations (Quarterly) Related Metrics
| Cash from Investing (Quarterly) | -43.48M |
| Cash from Financing (Quarterly) | 142.19M |
| Free Cash Flow | -24.03M |
| Free Cash Flow Per Share (Quarterly) | -0.0474 |
| Free Cash Flow to Equity (Quarterly) | -209.90M |
| Free Cash Flow to Firm (Quarterly) | -4.89M |
| Free Cash Flow Yield | -0.57% |